320 related articles for article (PubMed ID: 24416395)
21. Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients.
Surowiak P; Materna V; Kaplenko I; Spaczyński M; Dietel M; Lage H; Zabel M
Virchows Arch; 2005 Sep; 447(3):626-33. PubMed ID: 15968547
[TBL] [Abstract][Full Text] [Related]
22. Metallothionein isoform 3 as a potential biomarker for human bladder cancer.
Sens MA; Somji S; Lamm DL; Garrett SH; Slovinsky F; Todd JH; Sens DA
Environ Health Perspect; 2000 May; 108(5):413-8. PubMed ID: 10811567
[TBL] [Abstract][Full Text] [Related]
23. The impact of STAT3 and phospho-STAT3 expression on the prognosis and clinicopathology of ovarian cancer: a systematic review and meta-analysis.
Gao S; Zhang W; Yan N; Li M; Mu X; Yin H; Wang J
J Ovarian Res; 2021 Nov; 14(1):164. PubMed ID: 34789292
[TBL] [Abstract][Full Text] [Related]
24. Circulating microRNAs as novel potential diagnostic biomarkers for ovarian cancer: a systematic review and updated meta-analysis.
Wang X; Kong D; Wang C; Ding X; Zhang L; Zhao M; Chen J; Xu X; Hu X; Yang J; Gao S
J Ovarian Res; 2019 Mar; 12(1):24. PubMed ID: 30898156
[TBL] [Abstract][Full Text] [Related]
25. CD151 expression is frequent but unrelated to clinical outcome in head and neck cancer.
Nienstedt JC; Gröbe A; Lebok P; Büscheck F; Clauditz T; Simon R; Heumann A; Sauter G; Moebius C; Münscher A; Knecht R; Blessmann M; Heiland M; Pflug C
Clin Oral Investig; 2017 Jun; 21(5):1503-1508. PubMed ID: 27444451
[TBL] [Abstract][Full Text] [Related]
26. The role of metallothionein in oncogenesis and cancer prognosis.
Pedersen MØ; Larsen A; Stoltenberg M; Penkowa M
Prog Histochem Cytochem; 2009; 44(1):29-64. PubMed ID: 19348910
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors.
McCluggage WG; Young RH
Semin Diagn Pathol; 2005 Feb; 22(1):3-32. PubMed ID: 16512597
[TBL] [Abstract][Full Text] [Related]
28. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type.
Moh M; Krings G; Ates D; Aysal A; Kim GE; Rabban JT
Am J Surg Pathol; 2016 Mar; 40(3):419-32. PubMed ID: 26551622
[TBL] [Abstract][Full Text] [Related]
29. Nuclear metallothionein expression correlates with cisplatin resistance of ovarian cancer cells and poor clinical outcome.
Surowiak P; Materna V; Maciejczyk A; Pudełko M; Markwitz E; Spaczyński M; Dietel M; Zabel M; Lage H
Virchows Arch; 2007 Mar; 450(3):279-85. PubMed ID: 17235562
[TBL] [Abstract][Full Text] [Related]
30. Expression and clinical significance of survivin in ovarian cancer: A meta-analysis.
He X; Yang K; Wang H; Chen X; Wu H; Yao L; Ma S
PLoS One; 2018; 13(5):e0194463. PubMed ID: 29795564
[TBL] [Abstract][Full Text] [Related]
31. Expression of metallothionein in colorectal cancers and synchronous liver metastases.
Hishikawa Y; Kohno H; Ueda S; Kimoto T; Dhar DK; Kubota H; Tachibana M; Koji T; Nagasue N
Oncology; 2001; 61(2):162-7. PubMed ID: 11528256
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of alpha-methylacyl-CoA racemase, metallothionein and prostate specific antigen as prostate cancer prognostic markers.
Gumulec J; Masarik M; Krizkova S; Hlavna M; Babula P; Hrabec R; Rovny A; Masarikova M; Sochor J; Adam V; Eckschlager T; Kizek R
Neoplasma; 2012; 59(2):191-201. PubMed ID: 22248277
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological significance of metallothioneins in breast cancer.
Jin R; Huang J; Tan PH; Bay BH
Pathol Oncol Res; 2004; 10(2):74-9. PubMed ID: 15188022
[TBL] [Abstract][Full Text] [Related]
34. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation.
Paver EC; Cooper WA; Colebatch AJ; Ferguson PM; Hill SK; Lum T; Shin JS; O'Toole S; Anderson L; Scolyer RA; Gupta R
Pathology; 2021 Feb; 53(2):141-156. PubMed ID: 33388161
[TBL] [Abstract][Full Text] [Related]
35. Metallothionein is up-regulated under hypoxia and promotes the survival of human prostate cancer cells.
Yamasaki M; Nomura T; Sato F; Mimata H
Oncol Rep; 2007 Nov; 18(5):1145-53. PubMed ID: 17914565
[TBL] [Abstract][Full Text] [Related]
36. Prognostic roles of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in ovarian cancer: a meta-analysis of retrospective studies.
Zhao Z; Zhao X; Lu J; Xue J; Liu P; Mao H
Arch Gynecol Obstet; 2018 Apr; 297(4):849-857. PubMed ID: 29368160
[TBL] [Abstract][Full Text] [Related]
37. Adenoid cystic carcinoma of the salivary gland: a clinicopathological study of 49 cases and of metallothionein expression with regard to tumour behaviour.
Brazão-Silva MT; Cardoso SV; de Faria PR; Dias FL; Lima RA; Eisenberg AL; Nascimento MF; Loyola AM
Histopathology; 2013 Dec; 63(6):802-9. PubMed ID: 24102890
[TBL] [Abstract][Full Text] [Related]
38. A case-control study of Metallothionein-1 expression in breast cancer and breast fibroadenoma.
Sampaio FA; Martins LM; Dourado CSME; Revoredo CMS; Costa-Silva DR; Oliveira VA; Alves-Ribeiro FA; Silva BBD
Sci Rep; 2019 May; 9(1):7407. PubMed ID: 31092851
[TBL] [Abstract][Full Text] [Related]
39. Prognostic role of the cancer stem cell marker CD44 in ovarian cancer: a meta-analysis.
Shi YY; Jiang H
Genet Mol Res; 2016 Aug; 15(3):. PubMed ID: 27525945
[TBL] [Abstract][Full Text] [Related]
40. Development and Validation of an ERCC1 Immunohistochemistry Assay for Solid Tumors.
Bahamon BN; Gao F; Danaee H
Arch Pathol Lab Med; 2016 Dec; 140(12):1397-1403. PubMed ID: 27610644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
